Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Mesa Laboratories, Inc.
NASDAQ:MLAB
Intrinsic Alpha fair value
Locked
Current Price
$137.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +92.4% | N/A0 analysts |
| Revenue | N/A | N/A | +4.4% | +3.6% (3yr)1 analysts |
| Net Income | N/A | N/A | +93.3% | N/A1 analysts |
| EBIT | N/A | N/A | +77.3% | N/A — |
Analysis
Recent growth has been strongest in Net Income at +93.3% over three years. Forward estimates point to Revenue at +3.6% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Thermo Fisher Scientific Inc. NYSE:TMO | $259.44B | $700.22 | Fairly Valued | 25.3 | +20.59% |
Agilent Technologies, Inc. NYSE:A | $49.05B | $173.96 | Overvalued | 25.5 | +23.77% |
Revvity, Inc. NYSE:RVTY | $17.24B | $154.39 | Undervalued | 45.4 | +64.03% |
Bio-Techne Corporation NASDAQ:TECH | $11.44B | $72.80 | Overvalued | 78.3 | +25.52% |
Qiagen N.V. NYSE:QGEN | $10.30B | $49.89 | Undervalued | 18.6 | +17.44% |
Bio-Rad Laboratories, Inc. NYSE:BIO | $9.85B | $366.36 | Fairly Valued | 45.4 | +20.27% |
10x Genomics, Inc. NASDAQ:TXG | $7.07B | $58.19 | Overvalued | -196.0 | +266.77% |
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | $1.13B | $7.54 | Not rated | -7.1 | +103.87% |
Pacific Biosciences of California, Inc. NASDAQ:PACB | $611.98M | $1.96 | Not rated | -3.3 | +10.91% |
Standard BioTools Inc. NASDAQ:LAB | $279.27M | $0.71 | Not rated | -3.5 | -54.03% |
Continue the stock analysis
Jump to another research area for this company.